Cancer drugmaker Kura gives 6 new hires options on 153,750 shares
Kura Oncology announced new inducement grants, awarding nonstatutory stock options for 153,750 shares to six new employees. The options, granted on April 1, 2026, have an exercise price of $8.34 per share and will vest over four years, with a 25% cliff at one year, followed by monthly vesting. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and reflect Kura's ongoing hiring as it expands its commercial and pipeline activities.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced the grant of inducement awards consisting of nonstatutory stock options to six new employees. These options cover 153,750 shares of common stock and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $8.34 per share, and the options will vest over four years.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced the grant of inducement stock options to six new employees under its 2023 Inducement Option Plan. These options, covering 153,750 shares of common stock with an exercise price of $8.34 per share, were approved by the Compensation Committee as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards will vest over four years, subject to continued service.
Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume - Time to Buy?
Kura Oncology (NASDAQ:KURA) recently experienced unusually high trading volume, with shares increasing 53% from the previous session. Despite a consensus "Moderate Buy" rating from analysts with an average price target of $26.86, the company missed quarterly earnings and revenue estimates, reported negative margins, and saw insider selling activity. These factors raise concerns about the stock's fundamentals despite the recent trading surge.
Vanguard reports 0% ownership in Kura Oncology (NASDAQ: KURA)
The Vanguard Group has filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Kura Oncology (NASDAQ: KURA) common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their ownership separately, in accordance with SEC Release No. 34-39538. The filing, signed on March 27, 2026, indicates this is an administrative adjustment and does not imply a divestment of underlying holdings by Vanguard entities.
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages
Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus "Moderate Buy" rating from twelve analysts, with an average 1-year price target of $26.86. Despite recent weak quarterly results and insider selling, several institutional investors have increased their stakes. The company is a clinical-stage biopharmaceutical firm focusing on targeted oncology therapies.
Mizuho Cuts Kura Oncology (NASDAQ:KURA) Price Target to $25.00
Mizuho has reduced its price target for Kura Oncology (NASDAQ:KURA) stock from $30.00 to $25.00, while maintaining an "outperform" rating, suggesting a significant potential upside of 212.5% from its current price. This revision follows Kura Oncology missing its recent quarterly earnings and revenue expectations significantly. The company's stock is currently trading around $8.00 with a market capitalization of approximately $706.6 million, and analysts generally hold a "Moderate Buy" consensus rating with an average target of $26.86.
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Cuts Target Price to $25
Mizuho Securities has reiterated its Buy rating on Kura Oncology (KURA.US) but has revised its price target down to $25. This decision reflects the firm's ongoing positive outlook on the company despite the adjustment in the target price. Investors will likely be watching Kura Oncology for further developments.
KURA SEC Filings - Kura Oncology Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Kura Oncology Inc. (KURA) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms. It highlights significant events such as FDA approval for KOMZIFTI, clinical trial results, and collaboration agreements, offering AI-powered summaries to help investors understand key disclosures. The platform also details a recent 8-K filing regarding updated Phase 1a/1b results for ziftomenib, showing robust remission rates in AML patients and plans for Phase 3 trials.
Kura Oncology Inc stock surges on positive mid-stage trial results for key cancer drug candidate
Kura Oncology Inc's stock doubled after announcing positive mid-stage trial results for its lead cancer drug candidate, demonstrating strong efficacy in treating specific cancers. The promising data has led to analyst upgrades and increased investor attention, positioning Kura as a significant player in the biotech oncology landscape. Investors are now closely watching for upcoming milestones and Phase 3 trial developments.
KURA: Early Hematology Launch Execution Will Drive Future Upside Potential
Kura Oncology's fair value has slightly decreased to $32.27, primarily influenced by mixed analyst revisions regarding Komzifti's early launch metrics, safety, and market share. While bullish analysts highlight positive prescriber feedback and strong initial sales, bearish outlooks express caution over preliminary financial results, updated guidance, and the rate at which Komzifti can scale in a shared market. Recent company bylaw amendments also address corporate governance changes, including director nominations and stockholder proposals.
Kura Oncology (KURA) director exercises 10,000 options for shares
Kura Oncology director Thomas Malley exercised options to acquire 10,000 shares of common stock at $3.12 per share. These options were fully vested and represent the remaining options from that particular grant. Following this transaction, Malley directly holds 10,000 common shares and indirectly holds 139,557 common shares through Mossrock Capital, LLC.
Kura Oncology Inc Stock (ISIN: US50126D1028) Faces Post-Earnings Pressure Amid Komzifti Launch Challenges
Kura Oncology Inc. reported a significant revenue drop in Q4 2025, leading to stock pressure despite substantial cash reserves. The company's new AML drug, Komzifti, launched with promising initial sales but faces challenges, highlighting the volatility and risks within the biotech sector, particularly for European investors. Future performance hinges on the success of Komzifti's expansion and pending clinical trial data in 2026.
Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance
Kura Oncology is preparing for the commercial launch of KOMZIFTI, a drug aimed at treating acute myeloid leukemia (AML) in patients with specific mutations. The company projects a potential market opportunity of $7 billion, driven by KOMZIFTI's efficacy in the relapsed/refractory setting and future plans for combination therapies to expand its use into earlier treatment lines.
UBS Maintains Buy on KURA (Kura Oncology) March 2026, PT $15
UBS has maintained its Buy rating on Kura Oncology (KURA) but lowered its price target to $15 as of March 13, 2026. This decision reflects continued confidence in Kura's oncology pipeline, albeit with recalibrated near-term upside expectations. The analyst action led to a modest 1.11% intraday stock movement, emphasizing Kura's sensitivity to analyst signals due to its limited coverage and $752 million market cap.
Prosight Management LP Sells 422,668 Shares of Kura Oncology, Inc. $KURA
Prosight Management LP has reduced its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 13.3%, selling 422,668 shares and now holding 2,758,516 shares valued at approximately $24.41 million. This makes Kura Oncology the fourth-largest holding in Prosight's portfolio, representing about 3.17% of the company. Kura Oncology recently missed earnings expectations, reporting ($0.92) EPS against an expected ($0.72) and $17.34 million in revenue compared to an expected $34.71 million.
KURA SEC Filings - Kura Oncology Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Kura Oncology Inc. (KURA) SEC filings, including annual reports, quarterly earnings, and material event disclosures, alongside AI-powered summaries. Recent filings detail key milestones related to KOMZIFTI (ziftomenib), clinical trial data, commercialization strategies, and insider trading activities. Investors can access detailed regulatory documents and quick AI-generated insights on Stock Titan.
Implied Volatility Soars for Kura Oncology Option Contracts
Implied volatility for Kura Oncology Inc. (KURA) option contracts, particularly the April 17, 2026 $17.00 Call, has significantly increased, indicating market anticipation of substantial price movement. This surge occurs despite analyst estimates shifting from a projected profit to an anticipated loss for the current quarter. Experienced options traders might view this heightened volatility as an opportunity to sell premium, betting on time decay.
Implied Volatility Surging for Kura Oncology Stock Options
Implied volatility for Kura Oncology (KURA) stock options is notably high, particularly for the Apr 17, 2026 $17.00 Call, suggesting that the market anticipates a significant price movement. Despite this, the company currently holds a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics Industry, and recent analyst estimate revisions for the current quarter have been downward, indicating a potential trading opportunity for options traders.
(KURA) Risk Channels and Responsive Allocation
This article provides an analysis of Kura Oncology Inc. (KURA), highlighting strong sentiment across all horizons and an exceptional 86.5:1 risk-reward setup. It outlines three institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The report also includes a multi-timeframe signal analysis with support and resistance levels.
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates
Kura Oncology Inc (NASDAQ: KURA) reported a first-quarter EPS of $-0.92, significantly missing the analyst estimate of $-0.26 by $0.66. The company's revenue for the quarter was $17.34 million, falling short of the consensus estimate of $74.52 million. Following the report, Kura Oncology Inc's stock closed at $8.55, showing a decline of 28.45% over the last three months but an increase of 11.04% over the past year.
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology
Kura Oncology's launch has been successful, with rapid market access and strong initial sales, aiming for leadership in the NPM1 mutant AML market and expansion into broader opportunities. The company anticipates multiple clinical data readouts this year for ziftomenib and darlifarnib, backed by solid financial standing and strategic collaborations, as highlighted in their recent Leerink Global Healthcare Conference presentation. This indicates a focus on advancing their precision oncology pipeline and market position.
Kura Oncology, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:KURA) 2026-03-06
Kura Oncology, Inc. (NASDAQ: KURA) released its Q4 2025 earnings call presentation, reporting an EPS of -$0.92, missing estimates by $0.43, and revenue of $17.34 million, a 67.83% year-over-year decrease that missed expectations by $18.12 million. The company published a slide deck in conjunction with the earnings call on March 6, 2026.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards of nonstatutory stock options to four new employees. These awards, totaling 44,700 shares of common stock, were approved in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize employment. Each stock option has an exercise price of $8.68 per share and vests over four years, contingent on continued service.
Kura Oncology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Kura Oncology, Inc. has seen a revision in its stock evaluation due to fluctuating market conditions, with its stock currently priced at $8.51. The company, a microcap in the Pharmaceuticals & Biotechnology sector, has shown mixed performance, outperforming the S&P 500 in the past month but lagging year-to-date. Technical indicators also present mixed signals, reflecting significant volatility and the need for updated assessment.
Kura Oncology (KURA) Grants Stock Options to New Employees
Kura Oncology (KURA) has granted 44,700 stock options to four new employees under its 2023 Inducement Option Plan, with an exercise price of $8.68 per share. These options vest over four years, contingent on continuous service. The biotechnology company, focused on cancer treatment, faces financial challenges including negative profitability and no revenue growth, despite a strong cash position and moderate analyst sentiment.
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) reported its Q4 2025 earnings, highlighting the successful commercial launch of Comzifty for relapsed/refractory NPM1-mutant AML, generating $2.1 million in net product revenue. The company is aggressively pursuing expansion into frontline AML and combination therapies, aiming for long-term leadership in menin inhibition with a total U.S. opportunity estimated at $7 billion. Kura Oncology also discussed its broader pipeline, including darlafarnib for solid tumors, and detailed strong early commercial performance, including favorable payer coverage and potential "step-editing" by some blue plans favoring Comzifty.
To recruit 4 new staff, Kura Oncology offers 44,700 stock options
Kura Oncology announced the grant of 44,700 inducement nonstatutory stock options to four new employees on March 2, 2026. These options, with an exercise price of $8.68, vest over four years, aligning with Nasdaq Listing Rule 5635(c)(4). This move reflects the company's ongoing efforts to recruit and retain talent, set against recent positive fundamental updates like KOMZIFTI's FDA approval and strong cash resources.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of nonstatutory stock options to four new employees. These grants, totaling 44,700 shares of common stock, were approved under the Company’s 2023 Inducement Option Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $8.68 per share and will vest over four years, subject to continued employment.
Kura Oncology (KURA) begins KOMZIFTI sales and posts wider 2025 loss
Kura Oncology announced its Q4 and full-year 2025 financial results, reporting its first commercial sales of KOMZIFTI, generating $2.1 million in net product revenue. Despite this, the company posted a wider net loss of $81.0 million for Q4 2025 and $278.7 million for the full year, primarily due to increased R&D and SG&A expenses. Kura ended 2025 with $667.2 million in cash, expecting these funds plus anticipated collaboration payments to support the ziftomenib AML program through key Phase 3 results in 2028.
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid Rising Expenses
Kura Oncology Inc (KURA) reported a successful Q4 2025, driven by the commercial launch of KOMZIFTI, generating $2.1 million in net product revenue. Despite an increase in R&D and administrative expenses, the company's net loss improved to $8 million from $19.2 million in the prior year. Key highlights include FDA approval, rapid NCCN guideline inclusion, strong payer coverage for KOMZIFTI, and a robust pipeline with multiple clinical updates anticipated in 2026.
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss
Kura Oncology (NASDAQ:KURA) experienced a significant gap down in its stock price after missing Q4 earnings and revenue expectations. The company reported an EPS of -$0.92 against an estimated -$0.42 and revenue of $17.34 million versus a $34.71 million estimate. Despite the earnings miss and insider share sales, analysts maintain an average "Moderate Buy" rating with a target price of $28.00, and institutional investors showed mixed activity in the stock.
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates
Kura Oncology Inc (NASDAQ: KURA) reported a significant earnings miss in the first quarter, with an EPS of $-0.92, which was $0.66 worse than the analyst estimate. The company's revenue of $17.34 million also fell short of the consensus estimate of $74.52 million. Despite this, InvestingPro rates Kura Oncology Inc's financial health as "good performance," and its stock has seen considerable volatility, down 28.45% in the last three months but up 11.04% over the last year.
Cancer pill KOMZIFTI begins sales as Kura posts $81M loss
Kura Oncology reported its Q4 and full-year 2025 financial results, including an $81 million net loss in Q4, despite generating $2.1 million in net product revenue from the initial five weeks of KOMZIFTI sales. KOMZIFTI, an FDA-approved cancer pill, also secured Orange Book patent protection until July 2044. The company finished 2025 with $667.2 million in cash and expects $180 million in collaboration payments to fund its KOMET-017 trials through 2028.
Kura Oncology: Q4 Earnings Snapshot
Kura Oncology Inc. (KURA) reported a significant loss of $81 million in its fourth quarter, translating to 92 cents per share, which missed Wall Street expectations of a 72-cent loss per share. The biopharmaceutical company's revenue of $17.3 million also fell short of the $29.8 million forecast by analysts. For the full year, Kura Oncology recorded a loss of $278.7 million, or $3.18 per share, on revenues of $67.5 million.
Kura Oncology Reports Early Commercial Success for KOMZIFTI™ (ziftomenib) with Strong Initial Revenue and Payer Support
Kura Oncology announced early commercial success for its newly launched drug, KOMZIFTI™ (ziftomenib), generating $2.1 million in net product revenue in Q4 2025 despite an increased net loss of $81.0 million for the quarter. The drug, approved for relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation, has achieved rapid payer coverage and has patents extending to 2044, supporting long-term market exclusivity. Kura Oncology plans to advance ziftomenib through multiple clinical milestones in AML and solid tumors in 2026, supported by a strong financial position of $667.2 million in cash and anticipated collaboration payments.
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology announced its Q4 and full year 2025 financial results, highlighting the early success of its KOMZIFTI launch with $2.1 million in net product revenue and rapid payer coverage. The company expects multiple clinical data milestones in 2026 for its AML and solid tumor programs, supported by a strong capital position of $667.2 million in cash and anticipated collaboration payments. Kura aims to advance ziftomenib's AML program and progress its solid tumor pipeline.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards to four new employees, consisting of nonstatutory stock options to purchase 44,700 shares of common stock. These awards, made under the Company's 2023 Inducement Option Plan, are a material inducement for their employment as per Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $8.68 per share and will vest over four years, subject to continued employment.
Kura Oncology (KURA) Set to Release Q4 Earnings
Kura Oncology (KURA) is set to release its Q4 earnings on March 5th, with analysts forecasting a significant year-over-year decline in both EPS (-122.7%) and revenue (-34.2%). Despite strong institutional ownership, the biotechnology company faces financial challenges including negative operating margins and a distressed Altman Z-Score, signalizing a potential risk of bankruptcy. Insider selling further indicates caution, while analysts maintain a moderate buy sentiment with a target price of $31.7.
Kura Oncology Inc expected to post a loss of 61 cents a share - Earnings Preview
Kura Oncology Inc is projected to report a loss of 61 cents per share, according to an earnings preview. This financial outlook highlights the expected performance of the company, as analyzed by Reuters. The information is based on data provided by Refinitiv.
Wall Street Zen Downgrades Kura Oncology (NASDAQ:KURA) to Sell
Wall Street Zen downgraded Kura Oncology (NASDAQ:KURA) from "hold" to "sell," despite a broader analyst consensus of "Moderate Buy" with an average target price of $28.00. Shares opened at $8.73, and insiders sold nearly 60,000 shares worth approximately $537,000 in the last quarter, though they still own 6.4% of the company. Other analysts, including Wedbush and Barclays, recently reaffirmed "outperform" or "overweight" ratings with higher price targets.
Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research
Zacks Research upgraded Kura Oncology (NASDAQ:KURA) from a "strong sell" to a "hold" rating, contributing to a mixed but generally positive analyst outlook with an average price target of $28.00. Despite recent insider stock sales totaling $537,176, insiders still maintain a 6.40% ownership stake. The company currently has a market capitalization of $759.68 million and is trading with a negative P/E ratio.
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of "Moderate Buy" by Brokerages
Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of "Moderate Buy" from twelve brokerages, with an average 12-month price target of $28.00. Despite this, insiders have recently sold shares, and the company's stock currently trades at $8.73 with a market capitalization of approximately $760 million. Analysts from UBS Group, Zacks Research, Wall Street Zen, Leerink Partners, and Citigroup have provided varied ratings and price targets for KURA over the past few months.
Kura Oncology, Inc. (KURA): Investor Outlook Reveals 275% Upside Potential
Kura Oncology, Inc. (NASDAQ: KURA) shows significant potential in the biotechnology sector with a market capitalization of $752.7 million and a focus on innovative cancer treatments. Analysts have set an average target price of $32.45, suggesting a substantial upside of 275.20% from its current stock price of $8.65. While the company is in a developmental stage with negative financials indicative of heavy R&D investment, strong analyst support and strategic collaborations with major pharmaceutical companies bolster its long-term prospects.
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology, Inc. announced it will report its fourth-quarter and full-year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the results and provide a corporate update. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, and is commercializing KOMZIFTI™ for NPM1-mutated acute myeloid leukemia.
Cancer-focused biopharma Kura Oncology sets March 5 call on 2025 results
Kura Oncology (Nasdaq: KURA) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the results and provide a corporate update. Investors can access the live webcast and archived replay via the Investors section of the company website.
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology, Inc. announced it will release its fourth quarter and full-year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. The company's management will host a conference call and webcast to discuss these results and provide a corporate update. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, with an FDA-approved drug, KOMZIFTI™, for NPM1-mutated acute myeloid leukemia.
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology, Inc. announced its participation in three upcoming investor conferences: the TD Cowen Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Global Healthcare Conference, all scheduled for March 2026. Live audio webcasts of these presentations will be available on the company's website, with archived replays provided afterwards. Kura Oncology focuses on developing precision medicines for cancer treatment, with a pipeline of small molecule drug candidates and the FDA-approved drug KOMZIFTI™.
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology, Inc. announced its participation in three upcoming investor conferences: the TD Cowen Health Care Conference on March 4, 2026, the Leerink Partners Global Biopharma Conference on March 10, 2026, and the Barclays Global Healthcare Conference on March 12, 2026. Live audio webcasts and archived replays will be available on the company's website. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer.
Biotech firm Kura Oncology maps three March investor talks
Kura Oncology will participate in three investor conferences in March 2026: the TD Cowen Health Care Conference on March 4, the Leerink Partners Global Biopharma Conference on March 10, and the Barclays Global Healthcare Conference on March 12. Live audio webcasts of these presentations, along with archived replays, will be accessible through the Investors section of Kura's website. The company is focused on developing precision medicines for cancer treatment, including its FDA-approved drug KOMZIFTI™.
